Page 1,682«..1020..1,6811,6821,6831,684..1,6901,700..»

Immoral Uses of Biotechnology Even With Good Intentions Are Nevertheless Evil – National Catholic Register

Posted: February 6, 2017 at 11:48 am

Commentary | Feb. 3, 2017

Immoral Uses of Biotechnology Even With Good Intentions Are Nevertheless Evil

Should Christians face unethical uses of biotechnology with despair and resignation or with hope and determination?

Ive spent the last decade writing and speaking about the remarkable and terrifying world of biotechnology from a Catholic perspective. Many times Ive felt like Frodo Baggins at the gates of Mordor, looking upon Mt. Doom with despair and dread.

Ive never felt this more acutely than in the past few months. A series of recent headlines have renewed my sense of hopelessness in the face of the never-ending assault on the dignity of human life by modern biotechnology.

The gloom began to settle when it was revealed that a Swedish scientist is editing the DNA of healthy human embryos.Fredrik Lanner,a developmental biologist, is using a new gene-editing technique called CRISPR to disable some genes in healthy human embryos to see how those genes affect development. He and his team are intentionally modifyingotherwise healthy IVFembryos so they cannot develop properly.

Anin-depth story byNPRreveals that while the reporter was observing thegeneticmanipulation of five donated IVF embryos, one didnt survive the thawing process and one perished after being injected with the experimental gene-editing tool. Of the three who survived, one continued to divide, but not for long.All of the embryos were to be destroyedbefore they are 15 days old,as the law in Sweden dictates. Lanner insists that his research is critical to understanding human development, which, in turn, will shed light on infertility and disease.

Lanners work makes many ethicists and scientists extremely nervous. Jennifer Doudna, the co-inventor of CRISPR, along with other heavy-hitting scientists,havecalled for a voluntary moratorium on any editing of human embryosfor fear that it will lead to the creation of genetically modified children. Marcy Darnovsky, of the left-leaning Center for Genetics and Society, explains why she and her group havebeen so vocal in their opposition to the modification of human embryos. She told NPR: The production of genetically modified human embryos is actually quite dangerous. ... When youre editing the genes of human embryos, that means youre changing the genes of every cell in the bodies of every offspring, every future generation of that human being. So these are permanent and probably irreversible changes that we just dont know what they would mean.

Then came the revelation that a U.S. doctor traveled to Mexico to create the first baby intentionally engineered to have three genetic parents. This technique, misnamed mitochondrial replacement or MR, seeks to eliminate the transmission of genetic disease through the mitochondria.Mitochondria are small but abundant organellesoutside the nucleusinthe cytoplasmof our cells that make energy. They have their own DNA called mtDNA. We inherit our mtDNA solely from our mothers. A woman who carries a deleterious mutation in her mtDNA cannot help but pass that on to her offspring.

There are various MR techniques that replace the mitochondria of a woman with mitochondrial disease with the mitochondria of a donor femalein the IVF process.Essentially, MR creates a genetically alteredembryo with the genetic material from three people, one man and two women.

MR had only undergone limited study in primates before getting approval in the United Kingdom for use in fertility clinics to make babies. Little is known about the complexcommunication between the DNA in the nucleus and the DNA in the mitochondria,and so there is little data on the effects ofa mismatch between the nuclear DNA and mtDNA.

Alsoin all MR, its the nucleus thats being moved from cell to cell, not the mitochondria which is why mitochondrial replacement is such a misnomer.This makes MR acousin to cloning, which also transplants the nucleus of one cell into anotherto make a new organism. MR brings with it many of the same risks.Scientists are concerned about the health of the resulting children.

In anopen letterto the U.K. Parliament, Dr. Paul Knoepfler, a vocal American stem-cell researcher, warned: Even if, hypothetically, this technology might help avoid some people from having mitochondrial disorders (and thats a big if), the bottom line is that there is an equal or arguably greater chance that it will tragically produce very ill or deceased babies.

MRis also a germ-line genetic modification, which means that any girl born with this technique will pass her genetic modification on to her children.

A recent review in Nature reveals that MR leaves a tiny percentage of mutant mitochondria behind, and sometimes the mutant mitochondria rapidly divide and overtake the healthy mitochondria. Shoukhrat Mitalipov, head of the Center for Embryonic Cell and Gene Therapy at the Oregon Health and Science University, reported a 15% failure rate where mitochondrial defects returned. Mitalipov told NPR, That original, maternal mitochondrial DNA took over, and it was pretty drastic. There was less than 1% of the original maternal mitochondrial DNA present after replacement with donor DNA and before fertilization, and yet it took over the whole cell later. University of California San Francisco professor Patrick OFarrell suggests that mutant mitochondria can resurge at any time in a developing three-parent child or even resurface in future generations.

For all these reasons, MR is not yet approved by the FDA in the United States,and may never be.So, when a Jordanian woman with mitochondrial disease wanted to have a child using MR, John Zhang, from the New Hope Fertility Center in New York City, had to perform the procedure in Mexico. He created five embryos,and, according toNewScientist.com,only one developed normally. That child is now 9 months old.

Zhang went to Mexico because, he said, there are no rules, and yet he insists he did the safe and ethical thingin the absence of any medical or ethical oversight. In an ironic twist, the couple is Muslim and so chose the MR technique that wouldnt destroy existing embryos.But it was clear that only male embryos would be transferred for gestation, because boys cant pass on the genetic modification. What happened to the other four embryos, however? Were they destroyed,discarded or frozen? If they were females, would they have been destroyed anyway to make sure they couldnt pass on any ill effects?

Darnovskycalledthis rogue experimentationand added, No researcher or doctor has the right to flout agreed-upon rules and make up their own. This is an irresponsible and unethical act.

Knoepflerrespondedto the news by remindingus that this is a living human experiment that is going to unfold over years and decades. It is also worth noting that this child is a genetically modified human being as a result of this technique.

Of course, these are happenings to despair of not only because of the sheer disregard for the sanctity of individual human lives, but because of the breakneck speed at which scientists are kicking ethical lines farther and farther down the road like a tin can. All the while, they insist that its for the good of humanity. I wonder: How can wetreatindividual members of the human species so callously and then, at the same time, say its for the good of the whole human race?

I fear there is no line we wont cross;no ethical boundary wewonttear down in the name of science.

On a daily basis, Im surrounded by science and scientists. Often, their response to this madness is that its going to happen anyway, and theres no way to stop it, which implies we must go along to get along all in the name of progress.

If I am Frodo, then they and the rest of society are Saruman giving in to the despair and making a deal with Sauron.In the film version of The Lord of the Rings, Saruman says to Gandalf: Against the power of Mordor there can be no victory. We must join with him, Gandalf. We must join with Sauron. It would be wise, my friend.

Gandalf replies, Tell me, friend, when did Saruman the Wise abandon reason for madness?

Indeed. When did science abandon reason for madness, ethics for recklessness?

So what shall we do? If wesuccumb to despair, we become like Saruman.

We always have prayer. Its time toadd human embryonic research and germ-line human genetic engineering to our list of life issues that we pray about.It doesnt matter whether we understand the finer points of the science or not.Praying for an end to abortion andassisted suicide is nolongerenough.

In addition to prayer, there are other things we can do. The first is to vote pro-life at every level of government, from city council to state assemblymen. Being pro-life isnt just about abortion, however. Its about protecting the sanctity of life from the beginning to the end. Pro-life legislators, even if they cannot overturn Roe v. Wade, can effect local and state laws and steer funding away from unethical research.

Secondly, we must fight for conscience rights for medical professionals. I envision a not-so-far-off world wheredoctorsare forced into making genetically engineered embryos and bringing these children to term simply because parents claim its their reproductive right to have the children of their design. Without conscience rights, unethical experimentation on the next generation will be rampant and unchecked.

We must, however, always have hope. Whenstaring downthe juggernaut that is modern biotechnology, I always remember Frodo Baggins.When he was faced with the seemingly impossible task of taking the One Ring to Mordor, instead of shying away because it was too hard, he said: I will take the Ring, though I do not know the way.

Rebecca Tayloris a

clinical laboratory specialist in molecular biology.

She writes about bioethics on her blog,Mary Meets Dolly.

Link:
Immoral Uses of Biotechnology Even With Good Intentions Are Nevertheless Evil - National Catholic Register

Posted in Biotechnology | Comments Off on Immoral Uses of Biotechnology Even With Good Intentions Are Nevertheless Evil – National Catholic Register

Opinion: Harry Boxer: Watch these two biotechnology stocks – MarketWatch

Posted: February 6, 2017 at 11:48 am

President Trump pressed Big Pharma executives to increase U.S. production and lower drug prices.

As biotechnology stocks have been showing momentum following a meeting between President Trump and pharmaceutical executives Tuesday, our two long investments to watch are in that sector. There are also several shorts among our charts to watch to play the potential downside in this near-term, toppy-looking stock market.

Gene-therapy company bluebird bio Inc. BLUE, -2.42% has a strong-looking chart. The stock recently broke out of a wedge pattern, in which its price range had narrowed for two months in essentially a sideways direction. The stock continued the upmove on Tuesday when it popped $5.90, or over 8%, to $74.50, and followed through for another $1.10 on Wednesday to $75.60. The stock is now positioned to challenge its recent high at $79.70 from early December. A break through there could lead to a move into the mid-$80s, followed by a next target in the mid-$90s. With short interest of 9.2 its average volume, the price advance could be further fueled by short covering.

Cara Therapeutics Inc. CARA, +0.18% a cannabis-based biotech, has been steadily climbing since the start of the year. On Wednesday, the stock popped $1.17, or 7.6%, to $16.49 on 4.7 million shares, which is huge volume for this stock, the biggest since mid-November. The stock got as high as $17.20 intraday before pulling back into the close. It is a bit extended near the top of its channel and could pull back and consolidate before its next move, but momentum could carry it a bit further toward $18.

On the short side, Carters Inc. CRI, +0.09% continues lower since its July 2016 top above $112. On Wednesday, shares in the childrens wear retailer were down another $1.05, or 1.3%, to $82.70, on 690,100 shares traded. The stock appears headed toward the bottom of its declining channel in the $73-$74 range.

Signet Jewelers Ltd. SIG, -1.70% is also continuing lower. The stock rallied from the bottom of its declining price channel to the top in the last quarter of 2016, but has since broken down. Shares fell another 66 cents to $77.01 on 1.5 million shares traded on Wednesday. Watch for a test of the late-September low in the $72-$73 range. A takeout of that could drop the stock near its channel bottom in the low- to mid-$60s.

See Harrys video chart analysis on these and other stocks.

The writer has no holdings in any securities mention in this article.

Harry Boxer is the founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis and live chart presentations.

More here:
Opinion: Harry Boxer: Watch these two biotechnology stocks - MarketWatch

Posted in Biotechnology | Comments Off on Opinion: Harry Boxer: Watch these two biotechnology stocks – MarketWatch

The Puma Biotechnology Inc (PBYI) Insider Sells $95744.64 in Stock – DailyQuint

Posted: February 6, 2017 at 11:48 am

Puma Biotechnology Inc (NYSE:PBYI) insider Robert Charnas sold 3,008 shares of Puma Biotechnology stock in a transaction dated Wednesday, February 1st. The stock was sold at an average price of $31.83, for a total transaction of $95,744.64. Following the completion of the sale, the insider now directly owns 28,461 shares in the company, valued at approximately $905,913.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Puma Biotechnology Inc (NYSE:PBYI) traded up 0.75% during trading on Thursday, reaching $33.45. 527,529 shares of the company traded hands. The companys 50-day moving average price is $33.44 and its 200-day moving average price is $45.94. Puma Biotechnology Inc has a 52 week low of $19.74 and a 52 week high of $73.27. The companys market capitalization is $1.23 billion.

PBYI has been the topic of several research reports. J P Morgan Chase & Co set a $89.00 price objective on shares of Puma Biotechnology and gave the stock a buy rating in a research report on Monday, November 14th. Citigroup Inc. set a $88.00 price objective on shares of Puma Biotechnology and gave the stock a buy rating in a research report on Monday, November 14th. Stifel Nicolaus reaffirmed a buy rating and issued a $88.00 price objective on shares of Puma Biotechnology in a research report on Thursday, November 10th. Zacks Investment Research lowered shares of Puma Biotechnology from a buy rating to a hold rating in a research report on Tuesday, January 10th. Finally, Cowen and Company reaffirmed a market perform rating on shares of Puma Biotechnology in a research report on Tuesday, November 15th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the companys stock. Puma Biotechnology currently has a consensus rating of Hold and a consensus price target of $68.56.

A number of institutional investors have recently bought and sold shares of PBYI. Redmile Group LLC bought a new position in Puma Biotechnology during the third quarter valued at about $44,406,000. Janus Capital Management LLC boosted its position in Puma Biotechnology by 30.6% in the second quarter. Janus Capital Management LLC now owns 2,540,331 shares of the biopharmaceutical companys stock valued at $75,675,000 after buying an additional 594,821 shares in the last quarter. EverPoint Asset Management LLC bought a new position in Puma Biotechnology during the second quarter valued at about $13,406,000. BlackRock Fund Advisors boosted its position in Puma Biotechnology by 160.7% in the second quarter. BlackRock Fund Advisors now owns 602,071 shares of the biopharmaceutical companys stock valued at $17,936,000 after buying an additional 371,151 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Puma Biotechnology by 22.3% in the second quarter. Point72 Asset Management L.P. now owns 1,415,800 shares of the biopharmaceutical companys stock valued at $42,177,000 after buying an additional 258,100 shares in the last quarter. Institutional investors and hedge funds own 80.98% of the companys stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.

Originally posted here:
The Puma Biotechnology Inc (PBYI) Insider Sells $95744.64 in Stock - DailyQuint

Posted in Biotechnology | Comments Off on The Puma Biotechnology Inc (PBYI) Insider Sells $95744.64 in Stock – DailyQuint

More Volatility Ahead for Biotechnology Sector – Wall Street Journal (blog)

Posted: February 6, 2017 at 11:48 am

More Volatility Ahead for Biotechnology Sector
Wall Street Journal (blog)
After underperforming the S&P 500 over the past six months, the biotechnology sector is poised for more volatility ahead. The group drew plenty of attention on the campaign trail as both and Democratic candidate criticized the high prices for drugs ...

See the article here:
More Volatility Ahead for Biotechnology Sector - Wall Street Journal (blog)

Posted in Biotechnology | Comments Off on More Volatility Ahead for Biotechnology Sector – Wall Street Journal (blog)

Top Biotechnology Stock Picking: Intrexon Corporation (XON), Keryx Biopharmaceuticals, Inc. (KERX) – The Independent Republic

Posted: February 6, 2017 at 11:48 am

Intrexon Corporation (XON) ended last trading session with a change of 5.25 percent. It trades at an average volume of 1.33M shares versus 1.7M shares recorded at the end of last trading session. The share price of $22.04 is at a distance of 8.09 percent from its 52-week low and down -45.23 percent versus its peak. The company has a market cap of $2.61B and currently has 118.35M shares outstanding. The share price is currently -5.82 percent versus its SMA20, -16.17 percent versus its SMA50, and -17.92 percent versus its SMA200. The stock has a weekly performance of 2.04 percent and is -9.3 percent year-to-date as of the recent close.

Jan. 26, 2017 Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (XON) committed to enabling the study of life-threatening human diseases, has been awarded a subcontract to create genetically engineered miniswine models of sickle cell disease as part of a national resource that could lead to new treatments for the disorder.

The subcontract is with Leidos Biomedical Research, Inc., prime contractor for the Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute, part of the National Institutes of Health (NIH). Work under the subcontract will support the NIHs National Center for Advancing Translational Sciences (NCATS) in creating genetically engineered miniswine models of sickle cell disease. Exemplar Genetics will develop several versions of genetically engineered miniswine models of sickle cell disease that more accurately replicate the human pathology as compared to traditional research models.

Keryx Biopharmaceuticals, Inc. (KERX) recently recorded -0.55 percent change and currently at $5.45 is 75.24 percent away from its 52-week low and down -30.13 percent versus its peak. It has a past 5-day performance of 13.54 percent and trades at an average volume of 1.61M shares. The stock has a 1-month performance of -12.38 percent and is -7 percent year-to-date as of the recent close. There were about 106.55M shares outstanding which made its market cap $580.7M. The share price is currently -1.7 percent versus its SMA20, -5.27 percent versus its SMA50, and -1.49 percent versus its SMA200.

Nov. 18, 2016 Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, announced case study data, which showed that Auryxia (ferric citrate) lowered and maintained serum phosphorus levels in chronic kidney disease (CKD) patients on dialysis. These data were presented in a poster presentation at the American Society of Nephrologys 2016 Kidney Week taking place in Chicago.

Excerpt from:
Top Biotechnology Stock Picking: Intrexon Corporation (XON), Keryx Biopharmaceuticals, Inc. (KERX) - The Independent Republic

Posted in Biotechnology | Comments Off on Top Biotechnology Stock Picking: Intrexon Corporation (XON), Keryx Biopharmaceuticals, Inc. (KERX) – The Independent Republic

BioTime Acquires Retinal Repair Cell Therapy from UPMC – Genetic Engineering & Biotechnology News

Posted: February 6, 2017 at 11:45 am

Regenerative medicine company BioTime expanded its ophthalmology portfolio through the acquisition of global rights to the University of Pittsburgh Medical Centers (UPMC) stem cell-derived retinal repair platform IP. The cell therapy technology, developed in partnership with BioTime, generates 3-D retinal tissue from human pluripotent stem cells for use as implants to repair retinas in patients with advanced retinal degradation. The licensing deal has been made through UPMCs Innovation Institute.

We anticipate that this technology, co-developed with the UPMC lab for retinal repair and epigenetics, will allow us to generate three-dimensional laminated human retinal tissue in a controlled manufacturing process," said Michael D. West, Ph.D., co-CEO of BioTime. "This could lead to vision restoration treatments for a variety of blinding retinal degenerative diseases, particularly retinitis pigmentosa, macular degeneration, and diabetic retinopathy, among other diseases and conditions.

BioTime has developed its PureStem pluripotent stem cell technology for generating cell therapies against a range of degenerative diseases. The firms clinical pipeline includes cell therapies for human immunodeficiency virus (HIV)-related lipoatrophy, macular degeneration, leukemia, and spinal cord injury. The lead program, against HIV-related lipatrophy, is undergoing pivotal clinical trials. Preclinical programs are in development against non-small-cell lung cancer and orthopedics. BioTime is separately developing its HyStem hydrogel technology for culturing and delivering therapeutic cells. Its majority-owned OncoCyte subsidiary is leveraging stem cell expertise to develop noninvasive gene expression-based cancer diagnostics.

At the start of 2017, BioTime and its majority-owned subsidiary Cell Cure Neurosciences established a 8600-ft2 cGMP cell therapy manufacturing facility in Jerusalem.

See the rest here:
BioTime Acquires Retinal Repair Cell Therapy from UPMC - Genetic Engineering & Biotechnology News

Posted in Cell Therapy | Comments Off on BioTime Acquires Retinal Repair Cell Therapy from UPMC – Genetic Engineering & Biotechnology News

Trump’s travel restrictions will hurt cell therapy sector says ISCT – In-PharmaTechnologist.com

Posted: February 6, 2017 at 11:45 am

If reinstated, Donald Trumps order restricting travel to the US would hurt the cell therapy sector according to the International Society for Cellular Therapy (ISCT).

US President Donald Trump issued an executive order on January 27 that limited immigration from seven predominantly Muslim countries, halted refugee admission for 120 days, and barred all Syrian refugees.

Last Friday , a judge in Seattle suspended implementation of the order after lawyers representing Washington and Minnesota argued it was unconstitutional and discriminatory.

In response, Trump criticized the presiding judge and vowed to have the order reinstated. However, at the time of writing, nothing has been decided.

If reinstated, the travel restrictions will negatively impact the cell therapy sector according to the International Society for Cellular Therapy (ISCT) a Canada-based group representing doctors, regulators, researchers and industry which raised concerns in a statement today.

The US plays an essential part in cell therapy research as a leading country in the life science industry. It hosts the highest number of international conferences, critical for scientific collaboration and sharing of ideas.

The ISCT also highlighted the leading roles US investors and the FDA play in shaping the global cell therapy sector and warned against any regulations that restrict international collaboration.

ISCT views any policies that would prevent the free movement of properly credentialed scientists, patients, care givers and/or their families from entering the US, as significantly harmful to the sharing of key scientific findings and the ability to deliver cell therapy to all patients.

Read more from the original source:
Trump's travel restrictions will hurt cell therapy sector says ISCT - In-PharmaTechnologist.com

Posted in Cell Therapy | Comments Off on Trump’s travel restrictions will hurt cell therapy sector says ISCT – In-PharmaTechnologist.com

Experimental Stem Cell Therapy Stops Multiple Sclerosis In Its … – Vocativ

Posted: February 6, 2017 at 11:45 am

The prognosis for people affected by multiple sclerosis (MS), a degenerative autoimmune disorder that decimates the central nervous system, is a bleak one. The disease oftenbegins with a sudden burst of neurological symptoms like muscle spasms, vision problems, and trouble walking, then progresses differently, depending on which form of MS someone has. But eventually, nearly everyone with the disease comesto the point of being unable to move, breathe, or live independently. And sufferers on average live anywhere from five to ten years less than the general public.

Currently, the best medications we have available do little more than slow MS down, or tamp down peoples symptoms. But an experimental therapy continues to provide the first glimmers of something ground-breaking an actual way to stop one form of the disease in its tracks, and maybe even reverse some of the damage already done.

In this months Neurology, researchers detailed the final five-year-old results of a small clinical trial called HALT-MS. Twenty-four volunteers with MS who hadnt responded to conventional drugs were first given a powerful form of chemotherapy, high-dose immunosuppressive therapy (HDIT), that wiped out their immune system. Then they were given a transplant of their own stem cells taken out earlier, known as autologous hematopoietic cell transplant (HCT). These purified cells, the researchers theorized, would seed a new generation of uncorrupted white blood cells and reset the immune system, freezing MS in its place.

For the most part thats exactly what the combination HDIT/HCT therapy did. Nearly 70 percent of patients, five years in, have experienced no signs of the disease progressing. They havent had a relapse of symptoms, become more disabled, or had new brain lesions show up in imaging exams. Some have actually improved physically in the years since the treatment. And even those not in complete remission appear to be suffering less than before. Importantly, though the treatment isnt free of side-effects, there havent been severe ones. There were three deaths seen during the trial, all of whom experienced worsening MS, but none were attributed to the treatment.

The volunteers all had relapsing-remitting MS, the most common form, in which symptoms come and go with little rhyme or reason.

The evidence at this time is encouraging, but it isnt definitive, study author Dr. Linda Griffith, a researcher at the National Institute of Allergy and Infectious Diseases (NIAID), which sponsored the study, told Vocativ.

As Vocativ has previously reported, this isnt the first trial to find similar success rates for HDIT/HCT, though it does come with its own dangers. Patients can die from it, and like all kinds of chemotherapy, the deliberate weakening of the immune system often leads to more infections. It also doesnt seem to be as effective for more advanced types of MS, when the disease has stopped causing active inflammation, said Griffith. And while it could be promising for people in the earliest stages of MS, the research needed to promote it as a first-line treatment isnt there yet either, she added.

For now, the only trials of HDIT/HCT have been small and isolated. And though the effects of it when successful seem to extend as far out as 13 years later, its too early to call it a full-on cure. We still dont have a clear grasp of why MS happens in the first place, but its thought that multiple triggers like infections and unlucky genetics combine to increase peoples risk. So even if resetting someones immune system does treat MS completely, its plausible that some percentage of patients could fall victim to it again down the road, Griffith explained. We just dont know enough right now.

But Griffith is hopeful that larger, randomized studies will be underway within the next year or so. And if those prove to be as successful as the HALT-MS trial and others, the therapy could someday soon lead to a light at the end of tunnel for the millions of MS sufferers alive today.

Excerpt from:
Experimental Stem Cell Therapy Stops Multiple Sclerosis In Its ... - Vocativ

Posted in Cell Therapy | Comments Off on Experimental Stem Cell Therapy Stops Multiple Sclerosis In Its … – Vocativ

Cell Therapy – Technologies, Markets and Companies – Research and Markets – Yahoo Finance

Posted: February 6, 2017 at 11:45 am

DUBLIN, Feb 3, 2017 /PRNewswire/ --

Research and Markets has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

Research and Markets Logo

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2016, and projected to 2026.The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 303 of these are profiled in part II of the report along with tabulation of 292 alliances. Of these companies, 170 are involved in stem cells. Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 64 Tables and 22 Figures. The bibliography contains 1,200 selected references, which are cited in the text.

Key Topics Covered:

Part I: Technologies, Ethics & Regulations

Executive Summary

1. Introduction to Cell Therapy

2. Cell Therapy Technologies

3. Stem Cells

4. Clinical Applications of Cell Therapy

5. Cell Therapy for Cardiovascular Disorders

6. Cell Therapy for Cancer

7. Cell Therapy for Neurological Disorders

8. Ethical, Legal and Political Aspects of Cell therapy

9. Safety and Regulatory Aspects of Cell Therapy

Part II: Markets, Companies & Academic Institutions

10. Markets and Future Prospects for Cell Therapy

11. Companies Involved in Cell Therapy

12. Academic Institutions

13. References

For more information about this report visit http://www.researchandmarkets.com/research/4svftc/cell_therapy

Read More

Continue reading here:
Cell Therapy - Technologies, Markets and Companies - Research and Markets - Yahoo Finance

Posted in Cell Therapy | Comments Off on Cell Therapy – Technologies, Markets and Companies – Research and Markets – Yahoo Finance

Stem Cell Therapy Helps North Texas Teen Beat Asthma | NBC 5 … – NBC 5 Dallas-Fort Worth

Posted: February 6, 2017 at 11:45 am

A North Texas teenager who battled severe asthma for years is breathing free and clear again after doctors used stem cell therapy to temporarily treat his condition. (Published Monday, Jan. 30, 2017)

A North Texas teenager who battled severe asthma for years is breathing free and clear again after doctors used stem cell therapy to temporarily treat his condition.

Kenton Crenshaw, 18, of Crowley, never knew when his asthma would strike.

"Like 2, 3, 4 in the morning and it just hits me and I freak out," Crenshaw said.

"My asthma stopped me from doing lots of stuff that I wanted to do," he added.

Activity, even as light as walking outside, came with risk.

"I spent eight Christmases in the hospital because of asthma days or weeks long, birthdays it's just controlled my life," he said.

Crenshaw took countless medications but nothing seemed to help, so his family brought him to Dr. Bill Johnson at Innovations Medical in Dallas.

Johnson is one of a growing group of doctors using stem cell therapy to treat various diseases.

"The stem cells have the ability to reproduce and become other types of tissue, and that's what makes them so special," Johnson said.

Johnson took a small amount of fat from the Crenshaw through liposuction and separated the stem cells in a centrifuge.

He then mixes the stem cells with a solution, which is given back to patients, like Crenshaw, through intravenous therapy or breathing treatments.

"He has an overactive immune system with his lungs and airways, and what the stem cells can do is turn that down, decrease inflammation, and he's had a remarkable course," Johnson said, of Crenshaw.

It's been a few months since the treatments, and Crenshaw says he hasn't needed many of his medications.

"I felt like I never had asthma, like I feel perfect. I didn't do one breathing treatment in almost three months and I used to do four to six breathing treatments a day," he said.

The treatment isn't said to cure his asthma, but the results can last a year possible longer.

"I hope I never have an asthma attack the rest of my life," Crenshaw said.

Stem cell therapy treatments cost upwards of $7,000 and are not covered by insurance.

Published at 10:03 PM CST on Jan 30, 2017 | Updated at 10:41 PM CST on Jan 30, 2017

View original post here:
Stem Cell Therapy Helps North Texas Teen Beat Asthma | NBC 5 ... - NBC 5 Dallas-Fort Worth

Posted in Cell Therapy | Comments Off on Stem Cell Therapy Helps North Texas Teen Beat Asthma | NBC 5 … – NBC 5 Dallas-Fort Worth

Page 1,682«..1020..1,6811,6821,6831,684..1,6901,700..»